Wire Stories
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the...